Tumor mutational burden is a determinant of immune-mediated survival in breast cancer.

Oncoimmunology · 2018 · PMC6207420 · PMID 30386679

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not achieve significanceno p-value reported

However, while the FID subclass trended toward better OS (as compared to WID and PID) in the TNBC TMB-Hi tumors, it did not achieve significance likely owing in part to limited sample size (n = 69) and scant events (n = 6 deaths) (eFigure 9D,E in Supplement 1).

also in 1,397 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.